Niagen Bioscience, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M |
| Operating expenses | $66.9M | $53.9M | $56.4M | $61.4M | $68.6M |
| Cost of revenue | $46.2M | $38.0M | $32.8M | $29.3M | $26.0M |
| Cash from operations | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M |
| Share repurchases | $251,000 | $0 | — | — | — |
| Impairments | $0 | $0 | $3,000 | $0 | $0 |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M |
Shares outstanding 79.6M · Free float 22.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.